# Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

> **NCT06781983** · PHASE1 · RECRUITING · sponsor: **Innate Pharma** · enrollment: 145 (estimated)

## Conditions studied

- Advanced or Metastatic Solid Tumors

## Interventions

- **DRUG:** IPH4502

## Key facts

- **NCT ID:** NCT06781983
- **Lead sponsor:** Innate Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-24
- **Primary completion:** 2028-04
- **Final completion:** 2029-04
- **Target enrollment:** 145 (ESTIMATED)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06781983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06781983, "Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06781983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*